This suggests that FGF10 and FGFR2-IIIb are promising candidates as target molecules for new therapy against pancreatic cancer, and that therapeutic agents directed against these molecules may improve the prognosis of patients with this disease. The gene discussed is FGF10; the disease is pancreatic neoplasm.